PARSIPPANY, N.J., Aug. 22, 2024 (GLOBE NEWSWIRE) -- Embecta Corp. (“embecta”) (Nasdaq: EMBC), a global diabetes care company with a 100-year legacy in insulin delivery, today announced that management will participate in the following investor events:
2024 Wells Fargo Healthcare Conference
| • | Management will host one-on-one investor meetings on Wednesday, September 4, 2024, at the Encore Boston Harbor Hotel in Boston. |
2024 Morgan Stanley 22nd Annual Global Healthcare Conference
| • | Management will host a fireside session on Thursday, September 5, 2024, at 2:35 p.m. Eastern Time (ET) at the Marriott Marquis in New York. Audio webcasts of the presentations will be accessible under the “News & Events” section of the Company's investor relations website at https://investors.embecta.com. |
About embecta
embecta is a global diabetes care company that is leveraging its 100-year legacy in insulin delivery to empower people with diabetes to live their best life through innovative solutions, partnerships, and the passion of more than 2,000 employees around the globe. For more information, visit embecta.com or follow our social channels on LinkedIn, Facebook, Instagram and Twitter.
Contacts:
| Media | Investors |
| Christian Glazar | Pravesh Khandelwal |
| Sr. Director, Corporate Communications | VP, Head of Investor Relations |
| 908-821-6922 | 551-264-6547 |
| This email address is being protected from spambots. You need JavaScript enabled to view it. | This email address is being protected from spambots. You need JavaScript enabled to view it. |
| Last Trade: | US$13.94 |
| Daily Change: | 0.62 4.65 |
| Daily Volume: | 1,086,155 |
| Market Cap: | US$814.650M |
August 08, 2025 February 06, 2025 September 03, 2024 | |
Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...
CLICK TO LEARN MORE
ClearPoint Neuro is a global therapy-enabling platform company providing stereotactic navigation and delivery to the brain. Applications of our ClearPoint Neuro Navigation System include electrode lead placement, placement of catheters, and biopsy. The platform has FDA clearance and is...
CLICK TO LEARN MORE
